78 - Merck

Merck & Co. Januvia brand pills are displayed for a photograph at a pharmacy in Princeton, Illinois, U.S., on Monday, Oct. 23, 2017. Merck & Co. is scheduled to report quarterly earnings on October 27. Photographer: Daniel Acker/Bloomberg via Getty Images Daniel Acker — Bloomberg via Getty Images

The pharmaceutical giant raked in $40.1 billion in global sales in 2017, an increase of 1% from the year before. Merck’s superstar cancer immunotherapy drug Keytruda has continued to be the big performer; it alone brought in $1.46 billion in the first quarter of this year–an increase of 150% from the same time period last year. Success has been a mixed blessing, however. Keytruda now plays an outsize role in Merck’s portfolio, responsible for about 15% of the company’s sales. Moreover, plans to expand the drug’s applications have hit a snag: A collaboration with the biotech research firm Incyte to combine the drug with another experimental therapy has been recently halted.

Key Metrics & Financials (Last Fiscal Year)

Previous Rank69
Revenues ($M)$40122
Revenue Percent Change0.8%
Profits ($M)$2394.0
Profits Percent Change-38.9%
Assets ($M)$87872
Market Value — as of March 29, 2018 ($M)$146862

More from FORTUNE

Company Facts

SectorHealth Care
HQ LocationKenilworth, N.J.
CEOKenneth C. Frazier
CEO Title-
Years on Fortune 500 List24

See Full List


More from FORTUNE